Keyphrases
Phase II Study
100%
Eastern Cooperative Oncology Group
100%
Docetaxel
100%
Malignant Mesothelioma
100%
Partial Response
50%
Stable Disease
50%
Treatment Regimen
25%
Early Death
25%
Accruals
25%
Phase II Trial
25%
Am(III)
25%
Complete Response
25%
Median Survival Time
25%
Progressive Disease
25%
Median Time
25%
Time to Treatment Failure
25%
Gastrointestinal Toxicity
25%
Pulmonary Events
25%
Medicine and Dentistry
Oncology
100%
Mesothelioma
100%
Docetaxel
100%
Diseases
50%
Bleeding
25%
Phase II Trials
25%
Time to Treatment
25%
Infusion
25%
Median Survival Time
25%
Progressive Disease
25%
Gastrointestinal Toxicity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Mesothelioma
100%
Docetaxel
100%
Diseases
75%
Phase II Trials
25%
Bleeding
25%
Median Survival Time
25%
Gastrointestinal Toxicity
25%